Back to Agenda
How to Accelerate Utilization of Decentralized Clinical Trial: What are Issues to Perform Decentralized Clinical Trial?
Session Chair(s)
Junko Sato, PHD
Associate Executive Director
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Share the gap of Decentralized Clinical Trial (DCT) regulation in the EU, US and Japan. The speakers also touch how to overcome them. The session is helpful for sponsor which plan the trials.
Learning Objective : Explain DCT regulations in Japan, the US, and Europe and how to overcome their differences.
Speaker(s)
Experiences and expactation to DCT
Rasmus Enggaard, MPHARM, MSC
Novo Nordisk A/S, United States
Therapy Area Head, CardioRenal/Liver/RareD
DCT in Japan
Ruri Matsumoto, RPH
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Office of Non-clinical and Clinical Compliance I
DCT in US
Representative Invited
FDA, United States
Have an account?